Clinical Trials
Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients
Celtaxsys, Inc., a clinical stage pharmaceutical development company focused on advancing treatments for patients with rare inflammatory diseases, announced top line results of its Phase 2 EMPIRE-CF trial evaluating oral, once daily anti-inflammatory molecule, acebilustat, for the treatment of...
Clinical Trials
Servier and Galapagos announce start of global ROCCELLA Phase 2 clinical trial with S201086/GLPG1972 in osteoarthritis
Servier, an independent international pharmaceutical company, and the company Galapagos NV announce the start of a global Phase 2 trial with S201086/GLPG1972 in knee osteoarthritis patients: ROCCELLA. Servier and Galapagos have submitted and will further submit...
Clinical Trials
AbbVie Provides Update on Phase 3 Study of Ibrutinib in Blood Cancer Diffuse Large B-Cell Lymphoma and Ongoing Ibrutinib Clinical Program
AbbVie , a research-based global biopharmaceutical company, announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA®) in untreated diffuse large B-cell lymphoma , an aggressive form of non-Hodgkin lymphoma. IMBRUVICA is a first-in-class...
Clinical Trials
Codexis Doses First Subjects in Phase 1a Trial of CDX-6114
Codexis, Inc , a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered enzyme therapeutic being developed for the management of phenylketonuria (PKU). ...
Clinical Trials
Aminex Therapeutics Initiates First Clinical Trial of Novel Immunotherapy AMXT 1501 + DFMO in Cancer Patients
Aminex Therapeutics, Inc., a clinical-stage drug development company focused on advancing a novel cancer immunotherapy, announced it received clearance from the FDA to initiate the first Phase 1 clinical trial of its immuno-oncology drug candidate AMXT 1501. ...
Clinical Trials
MEI Pharma Presents Phase 1b Clinical Data for ME-401 in Patients with Indolent B-Cell Malignancies at the 2018 ASCO Annual Meeting
MEI Pharma, Inc a pharmaceutical company focused on leveraging its extensive development and oncology expertise to identify and advance new therapies for cancer. Announced that data presented at ASCO 2018 from a Phase 1b study of...
Clinical Trials
AstraZeneca provides update on GALATHEA Phase III trial for Fasenra in chronic obstructive pulmonary disease
AstraZeneca and MedImmune, its global biologics research and development arm, announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe COPD . The trial did not meet...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
